Literature DB >> 21637286

Mutation analysis of TET2, IDH1, IDH2 and ASXL1 in chronic myeloid leukemia.

C Roche-Lestienne, A Marceau, E Labis, O Nibourel, V Coiteux, J Guilhot, L Legros, F Nicolini, P Rousselot, M Gardembas, N Helevaut, C Frimat, F-X Mahon, F Guilhot, C Preudhomme.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21637286     DOI： 10.1038/leu.2011.139

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   12.883


× No keyword cloud information.
  21 in total

Review 1.  Systematic review of pre-clinical chronic myeloid leukaemia.

Authors:  Jew Win Kuan; Anselm Ting Su; Chooi Fun Leong; Motomi Osato; Goro Sashida
Journal:  Int J Hematol       Date:  2018-09-14       Impact factor: 2.490

2.  Low prevalence of the BCR-ABL1 fusion gene in a normal population in southern Sarawak.

Authors:  Jew Win Kuan; Anselm Ting Su; Siow Phing Tay; Isabel Lim Fong; Sho Kubota; Lela Su'ut; Motomi Osato; Goro Sashida
Journal:  Int J Hematol       Date:  2019-11-09       Impact factor: 2.490

3.  Tumor suppressor ASXL1 is essential for the activation of INK4B expression in response to oncogene activity and anti-proliferative signals.

Authors:  Xudong Wu; Ida Holst Bekker-Jensen; Jesper Christensen; Kasper Dindler Rasmussen; Simone Sidoli; Yan Qi; Yu Kong; Xi Wang; Yajuan Cui; Zhijian Xiao; Guogang Xu; Kristine Williams; Juri Rappsilber; Casper Kaae Sønderby; Ole Winther; Ole N Jensen; Kristian Helin
Journal:  Cell Res       Date:  2015-10-16       Impact factor: 25.617

Review 4.  The Hidden Pathogenesis of CML: Is BCR-ABL1 the First Event?

Authors:  Naranie Shanmuganathan; Susan Branford
Journal:  Curr Hematol Malig Rep       Date:  2019-12       Impact factor: 3.952

Review 5.  Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia.

Authors:  Susan Branford; Dennis Dong Hwan Kim; Jane F Apperley; Christopher A Eide; Satu Mustjoki; S Tiong Ong; Georgios Nteliopoulos; Thomas Ernst; Charles Chuah; Carlo Gambacorti-Passerini; Michael J Mauro; Brian J Druker; Dong-Wook Kim; Francois-Xavier Mahon; Jorge Cortes; Jerry P Radich; Andreas Hochhaus; Timothy P Hughes
Journal:  Leukemia       Date:  2019-06-17       Impact factor: 11.528

6.  Role of TET2 mutations in myeloproliferative neoplasms.

Authors:  Elodie Pronier; François Delhommeau
Journal:  Curr Hematol Malig Rep       Date:  2012-03       Impact factor: 3.952

Review 7.  The role of mutations in epigenetic regulators in myeloid malignancies.

Authors:  Alan H Shih; Omar Abdel-Wahab; Jay P Patel; Ross L Levine
Journal:  Nat Rev Cancer       Date:  2012-08-17       Impact factor: 60.716

8.  FISH analysis for TET2 deletion in a cohort of 362 Brazilian myeloid malignancies: correlation with karyotype abnormalities.

Authors:  Fábio Morato de Oliveira; Carlos Eduardo Miguel; Antônio Roberto Lucena-Araujo; Ana Silvia Gouvêa de Lima; Roberto Passetto Falcão; Eduardo Magalhães Rego
Journal:  Med Oncol       Date:  2013-02-07       Impact factor: 3.064

9.  Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia.

Authors:  Shady Adnan Awad; Matti Kankainen; Teija Ojala; Perttu Koskenvesa; Samuli Eldfors; Bishwa Ghimire; Ashwini Kumar; Soili Kytölä; Mahmoud M Kamel; Caroline A Heckman; Kimmo Porkka; Satu Mustjoki
Journal:  Blood Adv       Date:  2020-02-11

Review 10.  The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases.

Authors:  E Solary; O A Bernard; A Tefferi; F Fuks; W Vainchenker
Journal:  Leukemia       Date:  2013-11-13       Impact factor: 11.528
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.